Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734728PMC
http://dx.doi.org/10.4103/sjmms.sjmms_101_19DOI Listing

Publication Analysis

Top Keywords

follicular lymphoma
4
lymphoma saudi
4
saudi lymphoma
4
lymphoma group's
4
group's clinical
4
clinical practice
4
practice guidelines
4
guidelines diagnosis
4
diagnosis management
4
management follow-up
4

Similar Publications

Pediatric-type follicular lymphoma (PTFL) is an extremely rare B-cell lymphoma that primarily affects children and young adults, typically in individuals under 25 years old, with a median age of 15 years. Here, we report a rare case of PTFL in a 27-year-old adult male who presented with a slow-growing mass near his left ear. Initial CT scans of the neck revealed two oval-shaped, smooth, well-defined, homogeneously enhancing soft tissue density lesions in the superficial lobe of the left parotid gland.

View Article and Find Full Text PDF

Background: Clonal mature B-cell lymphoproliferative disorders (B-LPDs) are a heterogeneous group of neoplasia characterized by the proliferation of mature B lymphocytes in the peripheral blood, bone marrow and/or lymphoid tissues. B-LPDs classification into different subtypes and their diagnosis is based on a multiparametric approach. However, accurate diagnosis may be challenging, especially in cases of ambiguous interpretation.

View Article and Find Full Text PDF

Background: Obinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL). The clinical application of obinutuzumab has recently begun in China, but there is a lack of evidence to determine under which circumstances it should be considered the treatment of choice. A comprehensive assessment is necessary to evaluate the efficacy, safety, and cost-effectiveness of obinutuzumab in adult patients with FL.

View Article and Find Full Text PDF

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.

Signal Transduct Target Ther

January 2025

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Immunomodulatory agent lenalidomide is effective in treating follicular lymphoma (FL). We conducted the first trial of immunotherapy rituximab plus lenalidomide in newly diagnosed FL in China (NCT03715309). One-hundred and fifteen patients were enrolled and treated with rituximab 375 mg/m intravenously on day 0 and lenalidomide 25 mg orally on day 1-10 for 6 cycles of induction treatment, as well as lenalidomide for 6 cycles and rituximab for 8 cycles of maintenance treatment.

View Article and Find Full Text PDF

Surgery, especially if minimally invasive, still plays a role in the diagnosis of suspect lymphoproliferative lesions in challenging locations such as the retroperitoneum. Fluorescence guidance may help in such cases facilitating the visualization of highly vascularized lesions. Our recent experience with a 71-year-old woman with retroperitoneal lymphadenopathy and suspected lymphoma supports this hypothesis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!